Baseline quality of life predicts survival in patients with advanced colorectal cancer

Maisey, N.; Norman, A.; Watson, Maggie; Allen, Mark; Hill, Mark; Cunningham, David

doi:10.1016/s0959-8049(02)00098-9

Cited by 218 publications

(178 citation statements)

References 34 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…This issue has not been examined extensively in HCT, and it contrasts with a growing body of literature in other malignancies, where pre-treatment QOL has been shown to be a predictor of survival in advanced breast cancer, 23 lung cancer, 24,25 colorectal cancer, 26 melanoma 27 and multiple myeloma, 28 among others. Possible reasons for this might include the following: the high treatment-related morbidity and mortality of HCT in contrast to conventional chemotherapy; the rapidity of relapse and progression of aggressive hematologic malignancy after HCT; that HCT is a curative modality, whereas chemotherapy for metastatic solid tumors is generally not; and that patients may be undergoing HCT before the development of serious impairment as a result of their illness, as in stable-phase CML.…”

Section: Discussionmentioning

confidence: 99%

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Andorsky

Loberiza

Lee

2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Previous studies of quality of life (QOL) note compromised QOL after stem cell transplantation (HCT), but do not usually consider the impact of pre-transplantation deficits in QOL on post transplantation outcomes. To examine these associations, multivariate models for six self-reported QOL outcomes at 6 and 12 months were constructed, considering pre-transplantation clinical status and QOL, and subsequent clinical events. Outcomes measured overall subjective health, social functioning and agreement with statements such as 'Life has returned to normal.' Of 320 autologous and allogeneic HCT recipients who completed pre-transplantation surveys, 197 completed 6-month surveys and 175 completed 12-month surveys. Pre-transplantation overall health and mental health were independent predictors of all QOL outcomes at 6 months. Baseline physical health was also predictive of four of six outcomes at 12 months. In contrast, disease risk was predictive only of enjoying normal activities at 6 months. Relapse and chronic graft-versus-host disease were associated with poorer QOL. In conclusion, pretransplantation self-reported physical and mental health are more strongly associated with QOL after HCT than commonly noted baseline clinical predictors such as age and disease risk. Measurement of baseline QOL can help place the effects of the transplantation procedure in context.

show abstract

Section: Discussionmentioning

confidence: 99%

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Andorsky

Loberiza

Lee

2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Apart from humanitarian reasons, QOL has been linked to continuity of care, adherence to medical advice, and even length of survival. [1][2][3][4][5][6][7] Despite the growing body of literature over the past 20 years, understanding the determinants of QOL across all phases of cancer, ascertaining the relations between psychosocial and biomedical outcomes, and developing interventions to enhance QOL are still among the tasks confronting research into psychosocial oncology. attracted a wealth of research.…”

mentioning

confidence: 99%

Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy

Iconomou

Mega

Koutras

et al. 2004

Cancer

121

View full text Add to dashboard Cite

BACKGROUNDThe current study sought to delineate prospectively the rates and clinical course of emotional distress, cognitive impairment, and quality of life (QOL) in chemotherapy‐naive patients with cancer and to consider the determinants of global QOL.METHODSPatients who consented to participate were administered the European Organization for Research and Treatment of Cancer QLQ‐C30 questionnaire, the Mini‐Mental State Examination (MMSE), and the Hospital Anxiety and Depression Scale before and at the end of treatment (EOT).RESULTSOf the 102 patients initially assessed, 80 (78.4%) completed the study. Most aspects of QOL did not change considerably over time. At EOT, patients reported only significant increases in fatigue and significant decreases in sleep disturbance. Although no significant changes emerged in the rates of anxiety or depression throughout chemotherapy, nearly one‐third of the patients experienced severe emotional distress at both points in time. In addition, the authors observed neither significant alteration in the cognitive performance over time nor reliable associations between scores on the MMSE and subjective cognitive function, emotional distress, or QOL. Finally, depression proved to be the leading predictor of global QOL at baseline and at EOT.CONCLUSIONSThe results indicated that a significant proportion of Greek patients with cancer experienced intense anxiety and depression throughout chemotherapy and confirmed the importance of depression as a strong predictor of global QOL. Routine screening of emotional distress across all phases of cancer is mandatory because it will contribute to the identification of patients who are in need of pharmaceutical and/or psychologic intervention. Cancer 2004. © 2004 American Cancer Society.

show abstract

“…Nello specifico del carcinoma del colon-retto, l'Autore menziona 3 studi che sono focalizzati su questo tumore. Il primo è uno studio del 2002 [125] che ha mostrato che l'inclusione dei punteggi relativi a sintomi di diarrea, disturbi dell'alimentazione, astenia, capacità lavorativa, e qualità del riposo, permetteve di predire in maniera robusta l'OS, il secondo è un'analisi derivante dall'esame di 4 differenti trial clinici che avevano arruolato 501 pazienti affetti da CRC [126] e che ha mostrato che la sopravvivenza a 1 anno è stata pari, mediamente, al 72,5% tra i soggetti con QoL globale al di sopra del valore Cetuximab nel trattamento di prima linea del carcinoma metastatico del colon-retto mediano, e del 38,3% nel gruppo di pazienti con QoL globale al di sotto del valore mediano). Infine uno studio del 2008, che ha coinvolto 546 pazienti con CRC avanzato in 10 paesi [127], ha dimostrato che una riduzione di 10 punti dello score di funzionalità sociale EORTC QLQ-C30 determinava un 6% di aumento di rischio di morte prematura.…”

Section: Valutazione Della Qol Nel Carcinoma Del Colon-rettounclassified

Cetuximab in first line treatment of metastatic colorectal cancer

Barone

Belisari²,

Ciardiello

et al. 2012

View full text Add to dashboard Cite

The present health technology assessment report evaluates the clinical and economic profile of cetuximab in first-line metastatic colorectal cancer (mCRC) in Italy. The first part of the report addresses the epidemiological, clinical, social and economic impact of mCRC. In the second part, evidence of efficacy, safety and cost-effectiveness of cetuximab and its available alternatives is shown. Finally, a model-based economic evaluation aimed at comparing cetuximab-based regimens vs. alternative therapeutic strategies indicated in mCRC in Italy is presented. The model estimates the incremental cost-effectiveness of adding cetuximab to FOLFOX-4 or FOLFIRI based on KRAS status, vs. adding bevacizumab to FOLFOX-4 or vs. FOLFOX-4 or FOLFIRI alone. A theoretical analysis vs. panitumumab has also been performed, despite panitumumab is not yet reimbursed in Italy in first-line mCRC. Survival outcomes, quality of life and costs of patient management are estimated through a Markov model, using the Italian National Healthcare Service (NHS) perspective, over a 10 year period, taking into account KRAS status of patients. The results of the pharmaco-economic analysis show that cetuximab + FOLFOX-4 and cetuximab + FOLFIRI are associated with increased survival, increased cost and increased quality adjusted survival, compared to all other treatments currently indicated and reimbursed in Italy. Adding cetuximab to FOLFOX-4 or FOLFIRI, based on KRAS status shows favorable incremental cost-effectiveness ratio (ICER) vs. adding bevacizumab to FOLFIRI or vs. FOLFOX-4 or FOLFIRI alone. ICER of cetuximab (in combination with FOLFOX-4 or FOLFIRI), compared to currently reimbursed alternatives, is estimated between 6 and 13 thousand Euros per QALY gained, depending on alternative treatment. These estimates are robust in extensive sensitivity analyses. As a final result, both clinical and economic evidence analyzed in this health technology assessment leads to recommend cetuximab as preferred option for the first-line treatment of mCRC KRAS wild-type patients in Italy.

show abstract

Baseline quality of life predicts survival in patients with advanced colorectal cancer

Cited by 218 publications

References 34 publications

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Pre-transplantation physical and mental functioning is strongly associated with self-reported recovery from stem cell transplantation

Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy

Cetuximab in first line treatment of metastatic colorectal cancer

Contact Info

Product

Resources

About